Cargando…

Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil(®)) in C26 Tumor-Bearing Immunocompetent Mice

Doxorubicin (DXR) has been reported to have direct cytotoxicity against cancer cells and indirect immunotoxicity by modulation of host antitumor immunity. Hence, it may prevent cancer progression by a dual mechanism. Doxil(®), a formulation of DXR encapsulated in polyethylene glycol modified (PEGyla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takayama, Takuma, Shimizu, Taro, Abu Lila, Amr S., Kanazawa, Yuki, Ando, Hidenori, Ishima, Yu, Ishida, Tatsuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589973/ https://www.ncbi.nlm.nih.gov/pubmed/33086690 http://dx.doi.org/10.3390/pharmaceutics12100990

Ejemplares similares

Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model
por: Shimizu, Taro, et al.
Publicado: (2017)

Quantitative Cryo-TEM Reveals New Structural Details of Doxil-Like PEGylated Liposomal Doxorubicin Formulation
por: Nordström, Rickard, et al.
Publicado: (2021)

PEGylated liposomes: immunological responses
por: Mohamed, Marwa, et al.
Publicado: (2019)

Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil(®)) to Tumour Cells Using a Novel TIMP3 Peptide
por: Aldughaim, Mohammed S., et al.
Publicado: (2020)

Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
por: Tsukioka, Yoshihisa, et al.
Publicado: (2002)

Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of Doxil
por: Banciu, Manuela, et al.
Publicado: (2008)

A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer
por: Gibbs, D D, et al.
Publicado: (2002)

Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing
por: Doi, Yusuke, et al.
Publicado: (2016)

Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than Doxil(Ⓡ)
por: Zhang, Ruoshi, et al.
Publicado: (2020)

Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
por: Rios-Doria, Jonathan, et al.
Publicado: (2015)

Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing
por: Ngoune, Romeo, et al.
Publicado: (2018)

Liposome co-incubation with cancer cells secreted exosomes (extracellular vesicles) with different proteins expressions and different uptake pathways
por: Emam, Sherif E., et al.
Publicado: (2018)

Doxorubicin Embedded into Nanofibrillated Bacterial Cellulose (NFBC) Produces a Promising Therapeutic Outcome for Peritoneally Metastatic Gastric Cancer in Mice Models via Intraperitoneal Direct Injection
por: Ando, Hidenori, et al.
Publicado: (2021)

Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes
por: Yuan, Jiani, et al.
Publicado: (2017)

Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells
por: Wu, Xian, et al.
Publicado: (2018)

Lipid bubbles combined with low-intensity ultrasound enhance the intratumoral accumulation and antitumor effect of pegylated liposomal doxorubicin in vivo
por: Yokoe, Inoru, et al.
Publicado: (2021)

A Unique Gene-Silencing Approach, Using an Intelligent RNA Expression Device (iRed), Results in Minimal Immune Stimulation When Given by Local Intrapleural Injection in Malignant Pleural Mesothelioma
por: Ando, Hidenori, et al.
Publicado: (2020)

Bufalin-Loaded PEGylated Liposomes: Antitumor Efficacy, Acute Toxicity, and Tissue Distribution
por: Yuan, Jiani, et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006)

Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009)

Pegylated liposomal doxorubicin for myeloid neoplasms
por: Zhang, Cheng, et al.
Publicado: (2019)

The Therapeutic Effect of Human Serum Albumin Dimer-Doxorubicin Complex against Human Pancreatic Tumors
por: Kinoshita, Ryo, et al.
Publicado: (2021)

Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats
por: Ichihara, Masako, et al.
Publicado: (2010)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

A tale of the two PEGylated liposomal doxorubicins
por: Chou, Hunghsueh, et al.
Publicado: (2015)

Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance
por: Wei, Xiaohui, et al.
Publicado: (2018)

PEGylated versus Non-PEGylated pH-Sensitive Liposomes: New Insights from a Comparative Antitumor Activity Study
por: Nunes, Shirleide Santos, et al.
Publicado: (2022)

Cationic Polymethacrylate-Modified Liposomes Significantly Enhanced Doxorubicin Delivery and Antitumor Activity
por: Wang, Wenxi, et al.
Publicado: (2017)

Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
por: Moreira-Barros, Joana, et al.
Publicado: (2018)

Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
por: Yost, S., et al.
Publicado: (2019)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity
por: Liu, Yarong, et al.
Publicado: (2014)

Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma
por: Udhrain, Ashish, et al.
Publicado: (2007)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

EXTRAVASATION OF PEGYLATED-LIPOSOMAL DOXORUBICIN: FAVORABLE OUTCOME AFTER IMMEDIATE SUBCUTANEOUS ADMINISTRATION OF CORTICOSTEROIDS
por: MITSUMA, AYAKO, et al.
Publicado: (2012)

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)
por: Poveda, A., et al.
Publicado: (2005)

Site-specific PEGylation of lidamycin and its antitumor activity
por: Li, Liang, et al.
Publicado: (2015)

Magnetic delivery of antitumor carboplatin by using PEGylated-Niosomes
por: Davarpanah, Fereshteh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bpd824bajdd83do1e3daum6p3d